I thought that they had figured out a different way to get royalties on drug discovery demonstrations, without DIRECT competition? It seems that unless they find a BIG way to boost revenue potential, they will continue to be micro. With 10% of FDA licensees as customers, getting 100% would only move revenue from $14 million to $140 million (still micro).
Roughly speaking, CMN has gone up 35% since the beginning of the year. These Short Sellers/Doomers probably don't like that, but real investors should be happy. Particularly because CMN will continue to grow, and will have another stock split at some time in the future. It is a well run business, which has its investors in mind. Keep growing CMN, keep splitting!
If you look at the business model you see a fantastic opportunity for mankind, and as an aside, for any investor in SLP. Realizing that it is a small company, with a currently small marketplace, one should patiently wait for growth to reach the wonderous desires inherent in the business model. Management is adept at handling a company machine, but such handling is not creating the great potential implied. Perhaps the current benefits of the research is sufficient for management, they would know that more than me. I just wish there was some way for us simple investors to gain some big advantage also. It is selfish I know. But is running a corporate machine on "sleep mode" not also selfish. I am sure I will regret this post, sorry to offend anyone by my frustration.
obviously someone who has not studied the company, and just wants to create a false negative environment. Fortunately, most don't pay attention to these short promoters. Shorting has a value, but only if it is a real situation. CMN is not one of those situations.